Structured Abstract
Background Sporadic Alzheimer’s disease (sAD) lacks a unifying hypothesis that can account for the lipid peroxidation observed early in the disease, enrichment of ApoE in the central core of neuritic plaques, the hallmark plaques and tangles, and the selective vulnerability of entorhinal-hippocampal structures.
Objective We hypothesized that (1) high expression of ApoER2 (receptor for ApoE and Reelin) could help explain the selective anatomical vulnerability; and (2) lipid peroxidation of ApoE and ApoER2 contributes to sAD pathogenesis, by disrupting ApoE delivery and Reelin-ApoER2 signaling cascades.
Methods We conducted in vitro biochemical experiments, single-marker immunohistochemistry (IHC), and multiplex fluorescence-IHC (MP-IHC) in postmortem specimens from 26 individuals who died cognitively normal, with Mild Cognitive Impairment or with sAD.
Results In biochemical experiments, Lys- and His-enriched peptides within the binding domains of ApoE and ApoER2 and their corresponding recombinant proteins, were susceptible to attack by reactive lipid aldehydes, generating lipid-protein adducts and crosslinked ApoE-ApoER2 complexes. Using in situ hybridization alongside IHC and MP-IHC, we observed that: (1) ApoER2 is strongly expressed in terminal zones of the entorhinal-hippocampal ‘perforant path’ projections that underlie memory; (2) ApoE and lipid aldehyde-modified ApoE, Reelin, ApoER2 and several downstream components of Reelin-ApoER2 signaling cascades accumulated in the immediate vicinity of neuritic plaques in perforant path terminal zones in sAD cases; and (3) several ApoE/Reelin-ApoER2 pathway markers—including the ApoER2 ligand binding domain, Disabled homolog-1 (Dab1), and Thr19-phosphorylated PSD95 (marker of synaptic disassembly)—were higher in sAD cases than controls and positively correlated with histological progression and cognitive deficits.
Conclusion Results provide proof-of-concept that ApoE and ApoER2 are vulnerable to lipid aldehyde induced adduction and crosslinking and demonstrate derangements in multiple ApoE/Reelin-ApoER2-Dab1 axis components in perforant path terminal zones in AD. Findings provide the foundation for a unifying hypothesis implicating lipid peroxidation of ApoE particles and ApoE receptors in sAD in humans.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the intramural programs of the National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA) and National Institute on Neurological Diseases and Stroke (NINDS), NIH. Additional support was provided as a research gift from John M. Davis to the Laboratory of Clinical Investigation, NIA/NIH. We are grateful to the Banner Sun Health Research Institute Brain and Body Donation Program of Sun City, Arizona for the provision of human brain tissue. The Brain and Body Donation Program is supported by the NINDS (U24 NS072026 National Brain and Tissue Resource for Parkinson's Disease and Related Disorders), the NIA (P30 AG19610 Arizona Alzheimer's Disease Core Center), the Arizona Department of Health Services (contract 211002, Arizona Alzheimer's Research Center), the Arizona Biomedical Research Commission (contracts 4001, 0011, 05-901 and 1001 to the Arizona Parkinson's Disease Consortium) and the Michael J. Fox Foundation for Parkinson's Research.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All BBDP subjects provided written consent for study procedures, autopsy and sharing of de-identified data prior to enrollment. The study and its consenting procedures were approved by the Western Institutional Review Board of Puyallup, Washington.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The datasets and code are available from the corresponding author upon reasonable request.
